Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab before silicone oil removal to reduce postoperative hemorrhage
IRCT20231209060315N1Phase 4Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Incidence of vitreous hemorrhage after silicone oil removal, Incidence of iris neovascularization after silicone oil removal and 2 more. Started Mar 2024; status: completed.
02
Drugs
bevacizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on IRCT20231209060315N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231209060315N1.